Gilead Posts Strong Profit as HIV-Drug Sales Rise Amid Mixed Overall Revenue
Gilead Sciences reported a solid profit for the quarter, driven by strong demand for its HIV treatments including its new prevention drug. HIV drug sales rose about 4 % to $5.3 billion, aided by early revenues from the injectable prevention medication Yeztugo. However, overall product sales fell 2 % to $7.3 billion because of declines…